The Swing trader: Top High-Volatility Stocks v.2 (TA) AI trading robot has demonstrated its prowess once again, delivering impressive gains of +4.43% while trading AMGN (Amgen) over the previous week. This article will delve into the recent earnings results of AMGN and analyze the potential implications for traders.
Analyzing Earnings Results:
AMGN's latest earnings report, released on April 27, showcased the company's strong performance, surpassing expectations with earnings per share (EPS) of $3.98 compared to the estimated $3.82. This positive surprise indicates the company's ability to generate robust profits and highlights its potential for growth.
Market Capitalization:
With 41.92K shares outstanding, AMGN's current market capitalization stands at an impressive $122.14 billion. This figure reflects the market's valuation of the company based on its outstanding shares and demonstrates AMGN's substantial presence in the pharmaceutical industry.
Technical Analysis:
Aside from the encouraging earnings results, technical indicators also suggest a potential shift in AMGN's stock trend. On June 2, 2023, the Relative Strength Index (RSI) Oscillator for AMGN moved out of oversold territory. This development indicates that the stock may be transitioning from a downward trend to an upward trend, presenting an opportunity for traders.
To further analyze this shift, the A.I.dvisor examined 32 instances when the RSI indicator left oversold territory. In 20 out of those 32 cases, the stock price moved higher. This statistical observation implies that the probability of AMGN moving higher after leaving oversold territory is approximately 62%.
Implications for Traders:
Considering the positive earnings report, with AMGN surpassing EPS estimates, combined with the technical analysis indicating a potential shift in the stock's trend, traders may view this as an opportune moment. The positive earnings results and the RSI indicator's movement out of oversold territory provide a favorable backdrop for considering investment in AMGN, either through buying the stock or call options.
The RSI Oscillator for AMGN moved out of oversold territory on September 26, 2024. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In of the 31 cases the stock moved higher. This puts the odds of a move higher at .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in of 287 cases, the price rose further within the following month. The odds of a continued upward trend are .
AMGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 23, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on AMGN as a result. In of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for AMGN turned negative on October 21, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .
AMGN moved below its 50-day moving average on October 14, 2024 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AMGN crossed bearishly below the 50-day moving average on October 01, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 68, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: AMGN's P/B Ratio (24.331) is slightly higher than the industry average of (5.632). P/E Ratio (22.661) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (2.526) is also within normal values, averaging (3.004). Dividend Yield (0.031) settles around the average of (0.164) among similar stocks. P/S Ratio (5.402) is also within normal values, averaging (3.643).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AMGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of human therapeutic products based on cellular biology
Industry PharmaceuticalsMajor